Tirofiban (Aggrastat)

Tyrosine analog and PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX antagonist that inhibits PLATELET AGGREGATION and is used in the treatment of ACUTE CORONARY SYNDROME.

Also Known As:

Aggrastat; Agrastat; L 700462; L-700,462; L-700462; MK 383; MK-383; N-(Butylsulfonyl)-O-(4-(4-piperidyl)butyl)-L-tyrosine; Tirofiban Hydrochloride; Tirofiban Hydrochloride Monohydrate; L 700,462; L700,462

Networked: 936 relevant articles (187 outcomes, 315 trials/studies)

Relationship Network

Drug Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Amino Acids: 30675
  - Cyclic Amino Acids: 3
    - Aromatic Amino Acids: 467
      - Tyrosine: 10509
        Tirofiban: 936

Experts

1.	Cannon, Christopher P: 32 articles (11/2020 - 07/2002)
2.	Murphy, Sabina A: 26 articles (09/2008 - 07/2002)
3.	DiBattiste, Peter M: 24 articles (05/2005 - 05/2002)
4.	Valgimigli, Marco: 23 articles (08/2022 - 05/2004)
5.	Braunwald, Eugene: 21 articles (09/2008 - 07/2002)
6.	Gibson, C Michael: 19 articles (01/2012 - 07/2002)
7.	van 't Hof, Arnoud W J: 18 articles (01/2021 - 05/2004)
8.	Campo, Gianluca: 17 articles (01/2021 - 05/2004)
9.	Hamm, Christian: 16 articles (01/2021 - 07/2003)
10.	Ottervanger, Jan Paul: 14 articles (01/2021 - 05/2005)

Related Diseases

1.	Ischemic Stroke 12/01/2022 - "Safety and efficacy of different tirofiban administration routes on acute ischemic stroke patients with successful recanalization: A propensity score matching analysis." 11/17/2023 - "In a previously published clinical trial, we demonstrated that tirofiban was effective and safe in acute ischemic stroke (AIS) patients who did not undergo early recanalization treatments. " 01/01/2023 - "To investigate whether preceding intravenous thrombolysis combined with tirofiban in patients with acute ischemic stroke undergoing endovascular treatment is safe and effective. " 02/01/2010 - "In spite of the fact that the null hypothesis was not supported by our data, we found results supporting the safety (and potential efficacy) of ASA and tirofiban when used in the first hours of acute ischemic stroke. " 06/01/2023 - "Analysis of risk factors for the efficacy of tirofiban in the treatment of acute ischemic stroke."
2.	ST Elevation Myocardial Infarction 07/01/2012 - "We aimed to examine whether intracoronary high-dose bolus of tirofiban plus maintenance would result in improved clinical outcome in STEMI patients undergoing primary PCI in this pilot trial. " 11/01/2007 - "The On-TIME 2 trial evaluates whether pre-hospital initiation of high-dose bolus tirofiban is effective for patients with STEMI who are candidates to undergo PCI. " 01/01/2022 - "Tirofiban injection after emergency PCI is a beneficial treatment regime for patients with STEMI. " 07/01/2011 - "On the basis of the high-dose regimen, tirofiban may be considered useful in the management of patients with ST-elevation myocardial infarction who undergo primary angioplasty." 01/01/2009 - "On the basis of the demonstrated benefits of the high-dose bolus regimen, tirofiban may be considered useful in the management of patients with STEMI."
3.	Acute Coronary Syndrome 01/01/2009 - "The purpose of the study was to estimate the safety and the efficacy of the use of tirofiban, its influence on the function of the left ventricle of the heart and the clinical outcome of the patients with ST elevation acute coronary syndrome (ACS) during the rescue coronary angioplasty after the unsuccessful thrombolysis. " 04/01/2007 - "Evaluation on the safety and efficacy of tirofiban in the treatment of acute coronary syndrome." 01/01/2015 - "The objectives of this study are to explore the clinical effects of treatment with tirofiban for high-risk non-ST-segment elevation acute coronary syndrome (NSTE ACS) during peri-operative intervention operation period and to improve the level of clinical treatment. " 10/01/2013 - "[The prospective register study of domestic tirofiban for clinical application in acute coronary syndrome]." 07/01/2010 - "Randomised controlled trial evaluating the role of tirofiban in high-risk non-ST elevation acute coronary syndromes: an East Indian perspective."
4.	Thrombosis (Thrombus) 10/01/2023 - "Tirofiban use prior to PCI in high thrombus burden was associated with improved clinical and angiographic endpoints with similar adverse events compared to controls." 01/01/2018 - "This report represents the first case series of IC HDB tirofiban performed in North America and suggests that IC HDB tirofiban may represent an effective and safe strategy to achieve rapid thrombus resolution in ACS patients." 01/01/2015 - "The early use of tirofiban can make the thrombus fully dissolve and coronary blood flow remains in a good state, which is not only beneficial for myocardial perfusion but also helpful for deciding the length and side branch situation of coronary artery pathological changes." 11/01/2009 - "After tirofiban administration, a high-level thrombus resolution was obtained, with a significant improvement in coronary flow, and a successful PCI with stenting was performed. " 04/05/2010 - "Thrombus aspiration plus intra-IRA bolus administration of tirofiban combined with angioplasty may be related with improved myocardium perfusion, saved more myocardium, and resulted in a better clinical prognosis."
5.	Myocardial Infarction 07/01/2010 - "There was a significant reduction in the occurrence of fatal myocardial infarction (MI) (1 versus 8; p-value is 0.044) and non-fatal MI at Day 7 (1 versus 8; p-value is 0.044), and refractory ischaemia at the end of one month (14 versus 24; p-value is 0.04) and three months (25 versus 36; p-value is less than 0.01) in patients receiving tirofiban as compared to those receiving a placebo. " 01/01/2010 - "When compared with placebo, tirofiban was associated at 30 days with a significant reduction in mortality [OR = 0.68 (0.54-0.86); P = 0.001] and death or myocardial infarction (MI) [OR = 0.69 (0.58-0.81); P < 0.001]. " 03/01/2005 - "Pretreatment with tirofiban proved safe and resulted in a significantly lower corrected Thrombolysis in Myocardial Infarction frame counts (21 vs 34, P = .008) indicating improved myocardial blood flow. " 10/15/2003 - "Early administration of tirofiban before primary angioplasty resulted in nonsignificant improvement in initial coronary flow (Thrombolysis In Myocardial Infarction trial grade 2 or 3 flow, 39% vs 27%, p >0.20). " 11/11/2014 - "PPCI patients included in the Ongoing Tirofiban in Myocardial Infarction Evaluation (On-TIME) II study were candidates (N=861). "

Related Drugs and Biologics

1.	Heparin (Liquaemin)
2.	Glycoproteins (Glycoprotein)
3.	Abciximab (ReoPro)
4.	Aspirin (Acetylsalicylic Acid)
5.	Eptifibatide (Integrilin)
6.	Enoxaparin (Lovenox)
7.	Tissue Plasminogen Activator (Alteplase)
8.	omega-Chloroacetophenone (Mace)
9.	Platelet Membrane Glycoprotein IIb
10.	Platelet Membrane Glycoproteins

Related Therapies and Procedures

1.	Stents
2.	Therapeutics
3.	Thrombectomy
4.	Percutaneous Coronary Intervention
5.	Thrombolytic Therapy